Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread o

Trial Details

NCT ID
NCT06580314
Phase
PHASE3
Sponsor
NRG Oncology
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Bevacizumab
  • Biospecimen Collection
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Olaparib
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Anchorage, Alaska, United States|61.21806,-149.90028
  • Anchorage, Alaska, United States|61.21806,-149.90028
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Fayetteville, Arkansas, United States|36.06258,-94.15743

Key Eligibility Criteria

  • Patients with newly diagnosed, pathologically confirmed, Federation of Gynecology and Obstetrics (FIGO) stage III or IV ovarian cancer of the follo…
  • High grade serous
  • High grade endometrioid, and/or
  • Other epithelial ovarian cancer with BRCA1/2 deleterious alteration (germline or somatic)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →